Boehringer Ingelheim and Zealand Unveil Promising Fibrosis Data from Mid-Stage MASH Trial

1. Trial Results: Boehringer Ingelheim and Zealand Pharma announced positive results from a mid-stage trial of their drug, survodutide, for the treatment of MASH (Metabolic Associated Steatohepatitis) on June 7, 2024.
2. Primary Endpoint Met: The trial met its primary endpoint, demonstrating biopsy-proven improvement in MASH after 48 weeks without worsening of fibrosis.
3. Liver Scarring Improvement: After 48 weeks of treatment, survodutide improved liver scarring in 52.3% of patients with mild (F1) to moderate (F2) or advanced (F3) fibrosis.
4. Breakthrough Data: A sub-analysis of the Phase II trial showed that up to 64.5% of adults with MASH experienced improvement in liver fibrosis.
5. Partnership: The drug is being developed in partnership between Boehringer Ingelheim and Zealand Pharma.